Today: 18 January 2026
Subscribe
Browse Category

NVIDIA News 27 June 2025 - 11 July 2025

Nvidia Hits $4 Trillion, Grok Sparks Outrage, and the EU Cracks Down: The Week AI Changed Everything / Updated: 2025, July 11th, 12:01 CET

Nvidia Hits $4 Trillion, Grok Sparks Outrage, and the EU Cracks Down: The Week AI Changed Everything / Updated: 2025, July 11th, 12:01 CET

Nvidia surpassed a $4 trillion market capitalization, becoming the most valuable company and the engine of the AI revolution. Grok 4, Elon Musk’s xAI chatbot, produced antisemitic outputs after prompt manipulation, triggering investigations in France and the EU, Turkish restrictions, and leading to Linda Yaccarino’s resignation as X CEO. The EU released a final, voluntary General-Purpose AI Code of Practice,…
11 July 2025
···
NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Recent News and Highlights (Mid-2025) Table 1 – NVIDIA’s Explosive Revenue Growth (Fiscal year ends late January; FY2025 covers Feb 2024–Jan 2025) Fiscal Year Annual Revenue (USD) YoY Growth FY2023 (ended Jan 2023) $26.97 billion Macrotrends Macrotrends +0.2% Macrotrends (flat) FY2024 (ended Jan 2024) $60.92 billion Macrotrends Macrotrends +125.9% Macrotrends FY2025 (ended Jan 2025) $130.50 billion Nvidia Macrotrends +114.2% Macrotrends NVIDIA’s revenues more than doubled in both FY2024…
27 June 2025
··
1 … 21 22 23

Stock Market Today

  • Telix TLX valuation after first U.S. BiPASS Phase 3 patient dosed
    January 17, 2026, 7:02 PM EST. Telix Pharmaceuticals trades at A$11.48 after dosing the first U.S. patient in BiPASS Phase 3, spotlighting Illuccix and Gozellix in prostate cancer imaging. The update comes as the stock shows a 1-day gain of 2.96% and a 7-day gain of 2.14%. The rally has cooled, but the longer-term thesis remains intact. At a P/S of 3.9x, the company trades well below Australian biotech peers and a fair level near 7x, suggesting revenue is priced conservatively. A rough fair value via a DCF (discounted cash flow) model puts Telix near A$28.99 per share, implying roughly a 60% discount to today's price. The implied intrinsic value (the stock's true worth from fundamentals) could rise if earnings visibility improves. Risks include BiPASS results and slower Illuccix rollout. Illuccix and Gozellix potential keeps the narrative alive, but near-term clarity is needed.
Go toTop